⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

March 7, 2024Open Access

Figure S8 from Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma

Alyssa C. Flint Dana K. Mitchell Steven P. Angus Abbi E. Smith Waylan Bessler Li Jiang Henry Mang Xiaohong Li Qingbo Lu Brooke Rodriguez George E. Sandusky Andi R. Masters Chi Zhang Pengtao Dang Jenna Koenig Gary L. Johnson Weihua Shen Jiangang Liu Amit Aggarwal Gregory P. Donoho Melinda D. Willard Shripad V. Bhagwat D. Wade Clapp Steven D. Rhodes

View Full Paper

Ask AI

Bookmark

Share

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Abstract

Pharmacokinetic Evaluation of abemaciclib and LY3214996

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Flint et al. (2024) studied this question.

synapsesocial.com/papers/68e75573b6db6435876cd995 https://doi.org/10.1158/1078-0432.25359787

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Figure S8 from Combined CDK4/6 and ERK1/2 inhibition enhances anti-tumor activity in NF1-associated plexiform neurofibroma2024
2Table S3 from Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma2024
3Table S3 from Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma2024
4Table S3 from Combined CDK4/6 and ERK1/2 inhibition enhances anti-tumor activity in NF1-associated plexiform neurofibroma2024
5Table S3 from Combined CDK4/6 and ERK1/2 inhibition enhances anti-tumor activity in NF1-associated plexiform neurofibroma2024